Dawn of a New Era in the Microenvironment-Targeted Treatment for Multiple Myeloma
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 11742
Special Issue Editors
Interests: multiple myeloma; small-molecule inhibitors; myelomagenesis; chemoresistance; tumor microenvironment
Special Issue Information
Dear Colleagues,
Multiple myeloma (MM) is an incurable hematopoietic malignancy originating from plasma cells. The outcome of multiple myeloma treatment has improved dramatically with the introduction of novel agents such as proteasome inhibitors, immunomodulatory drugs, and immunotherapies. In particular, elucidation of the onset mechanism of myelomagenesis and drug resistance mechanism using the latest analytical technologies is accelerating the development of these agents. As a result, in some cases, it has become possible to achieve a complete response or minimal residual disease negativity that can be said to be almost curable. Importantly, MM cells are known to manipulate the bone marrow microenvironment by altering the expression pattern of cytokines and biasing the diversity of cells in the bone marrow, finally leading to drug resistance. Therefore, the further expansion of drug discovery targeting the bone marrow microenvironment, partly focused on cell adhesion mediated drug resistance (CAM-DR) caused by the interaction between MM cells and bone marrow stromal cells, is being eagerly attempted. To provide curative therapies in the future, it may be necessary to discuss the possibility of treatment targeting myeloma-specific cellular elements such as inflammatory stromal cells and immunosuppressive cells. This Special Issue will highlight some translational aspects of research on the treatment targeting the MM microenvironment.
Dr. Rikio Suzuki
Dr. Daisuke Ogiya
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- microenvironment
- chemoresistance
- CAMDR
- inflammatory stromal cell
- immunosuppressive cells
- proteasome inhibitor
- immunomodulatory drug
- immunotherapy
- novel drug
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
